CRISPR Gene Editing Market - 2023-2033
Description
CRISPR Gene Editing Market Overview:
The CRISPR Gene Editing Market was valued at US$ 4.21 Billion in 2023 and is anticipated to reach US$ 12.78 Billion by 2033, at a CAGR of 0.119 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the CRISPR Gene Editing Market.
This report delivers a comprehensive overview of the CRISPR Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding CRISPR Gene Editing Market. The CRISPR Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
CRISPR Gene Editing Market Scope:
By Product
• Kits and Reagents
• Instruments
By Gene Editing Modality
• Ex-Vivo Editing
• In-Vivo Editing
By Technology
• CRISPR/Cas9 Technology
• CRISPR/Cas12 Technology
• CRISPR/Cas13 Technology
• Base Editing
• Prime Editing
• Epigenetic Editing
• Others
By End User
• Biotechnology and Pharmaceutical Companies
• Academic and Research Institutes
• Agricultural and Livestock Industry
• Hospitals and Clinics
• Contract Research Organizations (CROs)
• Others
By Regional Market Analysis and Growth Opportunities
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
Key Players
• Thermo Fisher Scientific Inc.
• New England Biolabs
• Lonza Bioscience
• Merck
• Integrated DNA Technologies, Inc.
• Synthego
• GenScript
• Takara Bio Inc.
• QIAGEN
• Agilent Technologies, Inc.
Major Highlights
This report delivers a comprehensive overview of the CRISPR Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding CRISPR Gene Editing Market. The CRISPR Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
The CRISPR Gene Editing Market was valued at US$ 4.21 Billion in 2023 and is anticipated to reach US$ 12.78 Billion by 2033, at a CAGR of 0.119 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the CRISPR Gene Editing Market.
This report delivers a comprehensive overview of the CRISPR Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding CRISPR Gene Editing Market. The CRISPR Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
CRISPR Gene Editing Market Scope:
By Product
• Kits and Reagents
• Instruments
By Gene Editing Modality
• Ex-Vivo Editing
• In-Vivo Editing
By Technology
• CRISPR/Cas9 Technology
• CRISPR/Cas12 Technology
• CRISPR/Cas13 Technology
• Base Editing
• Prime Editing
• Epigenetic Editing
• Others
By End User
• Biotechnology and Pharmaceutical Companies
• Academic and Research Institutes
• Agricultural and Livestock Industry
• Hospitals and Clinics
• Contract Research Organizations (CROs)
• Others
By Regional Market Analysis and Growth Opportunities
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
Key Players
• Thermo Fisher Scientific Inc.
• New England Biolabs
• Lonza Bioscience
• Merck
• Integrated DNA Technologies, Inc.
• Synthego
• GenScript
• Takara Bio Inc.
• QIAGEN
• Agilent Technologies, Inc.
Major Highlights
This report delivers a comprehensive overview of the CRISPR Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding CRISPR Gene Editing Market. The CRISPR Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
243 Pages
- 1. Market Introduction and Scope
- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope
- 2. Executive Insights and Key Takeaways
- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Product
- 2.4. Snippet by Gene Editing Modality
- 2.5. Snippet by Technology
- 2.6. Snippet by End User
- 2.7. Snippet by Region
- 3. Dynamics
- 3.1. Impacting Factors
- 3.1.1. Drivers
- 3.1.1.1. Rising Incidence of Genetic Disorders and Demand for Curative Therapies
- 3.1.1.2. Increased Investment In R&D by Governments, Biotech, Pharma
- 3.1.2. Restraints
- 3.1.2.1. Delivery Challenges, Especially For In Vivo Editing
- 3.1.2.2. High Cost of Therapy Development, Manufacturing, and Eventual Commercialization.
- 3.1.3. Opportunity
- 3.1.3.1. Next-Generation Editing Technologies
- 3.1.3.2. AI And Machine Learning Integration
- 4. Strategic Insights and Industry Outlook
- 4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established Leaders with the Largest Marketing Brand
- 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter’s Five Forces Analysis
- 4.4.1. Bargaining Power of Suppliers
- 4.4.2. Bargaining Power of Buyers
- 4.4.3. Threat of Substitutes
- 4.4.4. Threat of New Entrants
- 4.4.5. Competitive Rivalry
- 4.5. Patent Analysis
- 4.5.1. Patent Expiry and Exclusivity
- 4.5.2. Key Patent Holders
- 4.5.3. Patent Litigations
- 4.5.4. Licensing Opportunities
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics
- 4.8.1. Price Benchmarking vs Competitors
- 4.8.2. Reimbursement Landscape
- 4.8.3. Pricing Trends by Region or Segment
- 4.8.4. Value-based Pricing Opportunities
- 4.9. SWOT Analysis
- 4.9.1. Strengths: Internal Advantages
- 4.9.2. Weaknesses: Internal Limitations
- 4.9.3. Opportunities: External Growth Possibilities
- 4.9.4. Threats: External Challenges
- 4.10. Supply Chain Analysis
- 4.10.1. Raw Material Sourcing
- 4.10.2. Manufacturing Locations
- 4.10.3. Distribution Channels
- 4.10.4. Logistics and Transportation
- 4.10.5. Supplier Risk Assessment
- 5. By Product
- 5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 5.1.2. Market Attractiveness Index, By Product
- 5.2. Kits and Reagents*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.2.3. CRISPR Kits
- 5.2.4. Guide RNA
- 5.2.5. Enzymes
- 5.2.6. Others
- 5.3. Instruments
- 6. By Gene Editing Modality
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gene Editing Modality
- 6.1.2. Market Attractiveness Index, By Gene Editing Modality
- 6.2. Ex-Vivo Editing *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. In-Vivo Editing
- 7. By Technology
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 7.1.2. Market Attractiveness Index, By Technology
- 7.2. CRISPR/Cas9 Technology *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. CRISPR/Cas12 Technology
- 7.4. CRISPR/Cas13 Technology
- 7.5. Base Editing
- 7.6. Prime Editing
- 7.7. Epigenetic Editing
- 7.8. Others
- 8. By End User
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
- 8.2. Biotechnology and Pharmaceutical Companies *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Academic and Research Institutes
- 8.4. Agricultural and Livestock Industry
- 8.5. Hospitals and Clinics
- 8.6. Contract Research Organizations (CROs)
- 8.7. Others
- 9. By Regional Market Analysis and Growth Opportunities
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gene Editing Modality
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.7.1. U.S.
- 9.2.7.2. Canada
- 9.2.7.3. Mexico
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gene Editing Modality
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.7.1. Germany
- 9.3.7.2. UK
- 9.3.7.3. France
- 9.3.7.4. Spain
- 9.3.7.5. Italy
- 9.3.7.6. Rest of Europe
- 9.4. Asia-Pacific
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gene Editing Modality
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.7.1. China
- 9.4.7.2. India
- 9.4.7.3. Japan
- 9.4.7.4. South Korea
- 9.4.7.5. Rest of Asia-Pacific
- 9.5. South America
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gene Editing Modality
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.7.1. Brazil
- 9.5.7.2. Argentina
- 9.5.7.3. Rest of South America
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gene Editing Modality
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10. Competitive Landscape and Market Positioning
- 10.1. Competitive Overview and Key Market Players
- 10.2. Market Share Analysis and Positioning Matrix
- 10.3. Strategic Partnerships, Mergers & Acquisitions
- 10.4. Key Developments in Product Portfolios and Innovations
- 10.5. Company Benchmarking
- 11. Company Profiles
- 11.1. Thermo Fisher Scientific Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.2.1. Product Description
- 11.1.2.2. Product Key Performance Indicators (KPIs)
- 11.1.3. Financial Overview
- 11.1.3.1. Company Revenue
- 11.1.3.2. Geographical Revenue Shares
- 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
- 11.1.4.1. Mergers & Acquisitions
- 11.1.4.2. Key Product Development Activities
- 11.1.4.3. Regulatory Approvals, etc.
- 11.1.4.4. SWOT Analysis
- 11.2. New England Biolabs
- 11.3. Lonza Bioscience
- 11.4. Merck
- 11.5. Integrated DNA Technologies, Inc.
- 11.6. Synthego
- 11.7. GenScript
- 11.8. Takara Bio Inc.
- 11.9. QIAGEN
- 11.10. Agilent Technologies, Inc. (LIST NOT EXHAUSTIVE)
- 12. Assumptions and Research Methodology
- 12.1. Data Collection Methods
- 12.2. Data Triangulation
- 12.3. Forecasting Techniques
- 12.4. Data Verification and Validation
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
